In a nutshell This study investigated the effects of adding elotuzumab to lenalidomide and dexamethasone to treat un-responsive multiple myeloma. The main finding was that patients treated with elotuzumab responded better to lenalidomide and dexamethasone. Some background Many patients respond well to treatment for multiple myeloma (MM). However some...
Read More
In a nutshell This study evaluated the outcomes of brentuximab vedotin (Adcetris) treatment for patients with relapsed (recurrent) or progressive (tumor grows or spreads) Hodgkin’s lymphoma (HL) after allogeneic (allo) stem cell transplantation (SCT). This study concluded that brentuximab vedotin is safe and effective for these patients. Some...
Read More
In a nutshell This article reviewed current treatment options for patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL). Some background DLBCL is one of the most common types of non-Hodgkin’s lymphoma. Typical first-line (primary) treatment involves chemoimmunotherapy....
Read MoreIn a nutshell This study aimed to compare the safety and effectiveness of duvelisib (Copiktra) and ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia. This study concluded that duvelisib was an effective treatment option for these patients. Some background Chronic lymphocytic leukemia (CLL) is the most common...
Read More
In a nutshell This study evaluated the safety and effectiveness of ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that ibritumomab tiuxetan...
Read More
In a nutshell The study looked at the safety and effectiveness of combining different chemotherapy drugs followed by stem-cell transplant for the treatment of unresponsive acute myeloid leukemia (AML). Researchers found that this method was safe and effective in the patients studied. Some background Acute myeloid leukemia is a cancer of the bone...
Read More
In a nutshell This study evaluated the effectiveness and safety of venetoclax (Venclexta) monotherapy (single-agent treatment) in patients with relapsed (cancer recurrence) or refractory (does not respond to initial treatment) mantle cell lymphoma (MCL). This study concluded that venetoclax monotherapy is promising, with minimal side effects. Some...
Read More
In a nutshell This study investigated the effectiveness and safety of brentuximab vedotin (Adcetris) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that brentuximab vedotin was effective and well-tolerated in these high-risk patients. Some background The...
Read MoreIn a nutshell This study investigated the effects of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma after stem cell transplant. Brentuximab vedotin appeared to be effective and safe for these patients. Some background Many patients with Hodgkin lymphoma (HL) are cured by standard therapies. However, some patients lose...
Read More
In a nutshell This article reviewed new treatment options for patients with relapsed Hodgkin’s lymphoma (HL). Some background The most common front-line (primary) chemotherapy regimen for the treatment of HL is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). 88 – 94% of patients with HL respond to this treatment. However, 10...
Read More
In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...
Read More
In a nutshell This study evaluated the effectiveness and safety of duvelisib in patients with chronic lymphocytic leukemia (CLL). This study concluded that duvelisib may be an effective new therapy with manageable side effects. Some background CLL is the most common type of leukemia in adults in the U.S. Although therapy options have increased, many...
Read More
